Suppr超能文献

贝达喹啉对缓慢生长非结核分枝杆菌的体外活性。

In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.

机构信息

Laboratory of Medical Microbiology, Institute of Experimental and Clinical Research, Université catholique de Louvain (UClouvain), Brussels, Belgium.

Laboratorio de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico city, Mexico.

出版信息

J Med Microbiol. 2019 Aug;68(8):1137-1139. doi: 10.1099/jmm.0.001025. Epub 2019 Jun 18.

Abstract

Bedaquiline (BDQ) is a recently approved antibiotic for the treatment of multidrug-resistant tuberculosis, but its potential against slow-growing mycobacteria (SGM) is still unknown. The objective of this study was to determine the in vitro activity of BDQ on SGM by assessing their MIC and minimal bactericidal concentration (MBC). The MIC of BDQ against 17 clinical isolates including Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium chimaera, Mycobacterium kansasii and Mycobacterium simiae species was determined by the resazurin microtitre assay and the MBC by the c.f.u. determination on 7H10 agar plates. BDQ has a bacteriostatic activity on all SGM tested with a MIC range from 0.03 to 0.007 µg ml and surprisingly a good bactericidal activity on the majority of the isolates tested with an MBC of 1-2 µg ml . Based on these preliminary results BDQ seems to be very promising for treatment of diseases caused by SGM.

摘要

贝达喹啉(BDQ)是一种最近批准用于治疗耐多药结核病的抗生素,但它对缓慢生长分枝杆菌(SGM)的潜在作用尚不清楚。本研究的目的是通过评估其 MIC 和最小杀菌浓度(MBC)来确定 BDQ 对 SGM 的体外活性。通过使用 Resazurin 微量滴定法测定 BDQ 对包括鸟分枝杆菌、胞内分枝杆菌、脓肿分枝杆菌、堪萨斯分枝杆菌和猿猴分枝杆菌在内的 17 株临床分离株的 MIC,并通过在 7H10 琼脂平板上测定 c.f.u.来确定 MBC。BDQ 对所有测试的 SGM 均具有抑菌活性,MIC 范围为 0.03 至 0.007 µg ml,并且令人惊讶的是,对大多数测试分离株具有良好的杀菌活性,MBC 为 1-2 µg ml。基于这些初步结果,BDQ 似乎非常有希望用于治疗由 SGM 引起的疾病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验